Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.

Nature communications·2026
Same author

Postoperative outcomes in older patients living with frailty and multimorbidity in the UK. Response to Br J Anaesth 2026; 136: 776-7.

British journal of anaesthesia·2026
Same author

Narrative exposure therapy in early intervention in psychosis services (NETp): protocol of a multi-site feasibility randomised controlled trial study .

BMJ open·2026
Same author

Correction: Dyńka et al. Ketogenic Diets for Body Weight Loss: A Comparison with Other Diets. <i>Nutrients</i> 2025, <i>17</i>, 965.

Nutrients·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

OpenMRF: A Modular, Vendor-Neutral Open-Source Framework for Reproducible Magnetic Resonance Fingerprinting using Pulseq.

ArXiv·2026
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

859

Optimizing therapy for mantle cell lymphoma.

Peter Martin1

  • 1Department of Medicine, Division of Hematology-Medical Oncology, Weill Cornell Medicine, New York, NY.

Hematology. American Society of Hematology. Education Program
|December 10, 2017
PubMed
Summary
This summary is machine-generated.

Mantle cell lymphoma (MCL) often presents with swollen lymph nodes, but uncommon nonnodal or explosive disease requires specialized management. Understanding MCL biology aids in developing tailored treatment strategies for diverse clinical presentations.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Experiment Videos

Last Updated: Feb 17, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

859
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Mantle cell lymphoma (MCL) typically presents with diffuse adenopathy, responding to rituximab and chemotherapy.
  • Uncommon presentations include nonnodal disease with indolent or aggressive courses, and rare explosive disease, often involving the central nervous system.

Purpose of the Study:

  • To highlight the diverse clinical presentations of mantle cell lymphoma beyond typical adenopathy.
  • To discuss the challenges in managing uncommon MCL presentations and the implications of new therapeutic agents.
  • To emphasize the role of evolving biological understanding in developing specialized treatment strategies for MCL.

Main Methods:

  • Review of clinical presentations and treatment outcomes in mantle cell lymphoma.
  • Analysis of challenges associated with nonnodal and explosive MCL disease.
  • Discussion of current and emerging therapeutic approaches and their complications.

Main Results:

  • While most MCL patients benefit from standard therapies, a subset exhibits nonnodal or explosive disease with varied clinical courses.
  • Explosive MCL presentations pose significant management challenges, frequently involving the central nervous system.
  • Newer agents offer improved quality of life but introduce novel complications upon treatment failure.

Conclusions:

  • Recognizing and understanding uncommon presentations of MCL is crucial for effective patient management.
  • Advances in understanding MCL biology are paving the way for more personalized and specialized treatment strategies.
  • Future research should focus on optimizing management for diverse MCL clinical scenarios and addressing complications of novel therapies.